Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-324 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-58 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-57509 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-58 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48 |
filingDate |
2005-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2010-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_853ea375703abeeaf476e23765b8243e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41b247c27d4a217e4ff56be55ff876b0 |
publicationDate |
2010-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CA-2500886-C |
titleOfInvention |
The use of cardiac hormones for assessing the risk of suffering from a cardiovascular complication as a consequence of volume overload |
abstract |
The present invention relates to the use of cardiac hormones, particularly natriuretic peptides, for assessment of risk of suffering from a cardiovascular complication, particularly heart disease or acute coronary syndrome, as a consequence of intravasal volume overload. In particular, the invention relates to a method for diagnosing the risk of a patient whose intravasal volume is increased or will be increased of suffering from a cardiovascular complication as a consequence of the increase of intravasal volume, comprising the steps of (a) taking a body fluid or tissue sample, and (b) measuring, preferably in vitro, the level of a cardiac hormone. The most preferred cardiac hormone in the context of the present invention is NT-proBNP. |
priorityDate |
2004-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |